Surprised that no one commented on #msg-82279247 (and #msg-82279355), which is pretty big news for BMY and PFE.
FWIW I consider the Eliquis data clinically interesting - but didn't see anything to add from a clinical perspective and don't think the Eliquis data swings the needle much for them (it is just one factor in many).